Race-ethnic differences in the association of genetic loci with HbA1c levels and mortality in U.S. adults: the third National Health and Nutrition Examination Survey (NHANES III)
© Grimsby et al.; licensee BioMed Central Ltd. 2012
Received: 12 October 2011
Accepted: 27 April 2012
Published: 27 April 2012
Hemoglobin A1c (HbA1c) levels diagnose diabetes, predict mortality and are associated with ten single nucleotide polymorphisms (SNPs) in white individuals. Genetic associations in other race groups are not known. We tested the hypotheses that there is race-ethnic variation in 1) HbA1c-associated risk allele frequencies (RAFs) for SNPs near SPTA1, HFE, ANK1, HK1, ATP11A, FN3K, TMPRSS6, G6PC2, GCK, MTNR1B; 2) association of SNPs with HbA1c and 3) association of SNPs with mortality.
We studied 3,041 non-diabetic individuals in the NHANES (National Health and Nutrition Examination Survey) III. We stratified the analysis by race/ethnicity (NHW: non-Hispanic white; NHB: non-Hispanic black; MA: Mexican American) to calculate RAF, calculated a genotype score by adding risk SNPs, and tested associations with SNPs and the genotype score using an additive genetic model, with type 1 error = 0.05.
RAFs varied widely and at six loci race-ethnic differences in RAF were significant (p < 0.0002), with NHB usually the most divergent. For instance, at ATP11A, the SNP RAF was 54% in NHB, 18% in MA and 14% in NHW (p < .0001). The mean genotype score differed by race-ethnicity (NHW: 10.4, NHB: 11.0, MA: 10.7, p < .0001), and was associated with increase in HbA1c in NHW (β = 0.012 HbA1c increase per risk allele, p = 0.04) and MA (β = 0.021, p = 0.005) but not NHB (β = 0.007, p = 0.39). The genotype score was not associated with mortality in any group (NHW: OR (per risk allele increase in mortality) = 1.07, p = 0.09; NHB: OR = 1.04, p = 0.39; MA: OR = 1.03, p = 0.71).
At many HbA1c loci in NHANES III there is substantial RAF race-ethnic heterogeneity. The combined impact of common HbA1c-associated variants on HbA1c levels varied by race-ethnicity, but did not influence mortality.
The prevalence of type 2 diabetes (T2D) is not equal among race-ethnic groups in the United States, with a prevalence of 12.8% in non-Hispanic blacks (NHB), 8.4% in Mexican Americans (MA), and 6.6% in non-Hispanic whites (NHW) aged 20 yrs or older . Diabetes-related complications also differ between race-ethnicities  and there is greater impact of diabetes on life-years in minority groups . Race-ethnic differences in environmental exposures and health care experiences  likely influence different outcomes for people with diabetes, but genetic differences may also play an important role. Despite recent advances in the study of T2D genetics, relatively little is known about how race-ethnic genetic differences contribute to inter-race variability in diabetes risk or diabetes-related traits.
Percent HbA1c (glycated hemoglobin) is an informative trait for diabetes diagnosis and management. It is accurate in quantifying chronic glycemic exposure of erythrocytes for the preceding 2–3 months, and there is a robust correlation between HbA1c levels and occurrence of diabetes complications [5, 6]. Recently, MAGIC (Meta-analyses of Glucose and Insulin related traits Consortium) identified ten genetic loci associated with HbA1c. The ten loci associated included three loci in or near genes likely involved in glycemic control pathways: G6PC2 (glucose-6-phosphatase catalytic subunit 2, MIM 608058), GCK (glucokinase, maturity onset diabetes of the young (MODY) 2, MIM 138079), and MTNR1B (melatonin receptor 1B, MIM 600804) and seven loci in or near genes likely to be involved in erythrocyte biology, including SPTA1 (spectrin alpha erythrocytic 1, MIM 182860), HFE (hemochromatosis, MIM 235200), ANK1 (ankyrin 1, MIM 612641), HK1 (hexokinase 1, MIM 142600), APT11A (ATPase Class VI, type 11A, MIM 605868), FN3K (fructosamine 3 kinase, MIM 608425), and TMPRSS6 (transmembrane protease serine 6, MIM 609862). Since MAGIC only included individuals of European ancestry, nothing is known about the impact of these risk alleles on HbA1c levels in non-European-ancestry populations.
Given the selection pressure by infectious diseases such as malaria on some erythrocyte-related genes in African populations [8–10] and the influence of erythrocyte genes on HbA1c[7, 11], we hypothesized that risk alleles at HbA1c-associated loci may have substantial race-ethnic frequency variation and that associations with HbA1c levels may also differ by race. Furthermore, since elevated HbA1c is associated with risk of cardiovascular disease or mortality [12–19], we hypothesized that an association between HbA1c-associated SNPs and mortality may exist and there may be race-ethnic differences in this association. Using 11 confirmed HbA1c-associated SNPs at ten loci , we compared NHB, MA, and NHW individuals from NHANES (National Health and Nutrition Examination Survey) III to test the hypotheses that there is significant race-ethnic variation in HbA1c risk (HbA1c-raising) allele frequency, risk-allele association with HbA1c levels and risk-allele association with mortality.
Study subjects from the third national health and nutrition examination survey
NHANES III was a nationally representative sample of the non-institutionalized civilian U.S. population collected using stratified multistage probability sampling. NHANES participants underwent a physical examination, phlebotomy, and a household interview . This study was limited to non-diabetic patients (aged 20 or older) with 8–23 hours of fasting prior to blood sampling. Blood from NHANES III Phase II (1991–1994) participants aged 12 or older were used to generate Epstein-Barr transformed lymphocyte cell lines for DNA extraction. Mortality data (death within a mean of 13.5 years of follow-up) were merged from the NHANES III mortality-linked data file. Race-ethnic group was assigned based on self-report. The survey asked each subject to categorize his/her race as “white,” “black,” or “other” and his/her ethnicity as “Mexican-American,” “other Hispanic,” or “not Hispanic.” Of 3,894 individuals with complete data for analysis, we excluded 149 who were not of NHB, MA or NHW race-ethnicity and 704 with diabetes (293 NHW, 167 NHB and 244 MA), leaving 901 NHB, 909 MA, and 1,231 NHW individuals in the analysis. Written informed consent was obtained from all subjects and this study was approved by the National Center for Health Statistics (NCHS) Ethics Review Board.
Diabetes definition and HbA1c measures
Individuals with diabetes were excluded to avoid the confounding effects of treatment on HbA1c. We defined diabetes as a fasting plasma glucose ≥ 7.0 mmol/L, report of a diagnosis of diabetes or use of hypoglycemic medications. HbA1c levels were measured using HPLC (Bio-Rad DIAMAT glycosylated hemoglobin analyzer system) .
SNP genotyping and allele frequencies
Genotyping was performed using Sequenom iPLEX. We genotyped 11 SNPs at ten loci shown among white non-diabetic individuals in MAGIC to have genome-wide significant association with HbA1c. We used SNP rs282606 as a proxy for ATP11A rs7998202 (CEU r2 = 1.0), SNP rs10830956 as a proxy for MTNR1B rs1387153 (CEU r2 = 1.0), and rs2022003 as a proxy for SPTA1 rs2779116 (CEU r2 = 0.927) [r2 for ASW and MEX populations not available]. The minimum call rate for genotyping was 95%. Allele frequencies of all SNPs were in Hardy Weinberg Equilibrium (HWE) based on National Center for Health Statistics standards (HWE rejected if p < 0.01 in ≥ 2 or more race-ethnic groups). We compared NHANES observed allele frequencies with those available from HapMap (http://hapmap.ncbi.nlm.nih.gov/, Release 27, Phases II and III, NCBI build 36), comparing NHW with CEU (Utah residents with Northern and Western European ancestry from the CEPH collection), NHB with ASW (African ancestry in Southwest USA), and MA with MEX (Mexican ancestry in Los Angeles, California).
Genotype risk score
We calculated a genotype risk score to test the collective association with HbA1c of 11 SNPs at 10 loci (2 uncorrelated SNPs at ANK1). We assumed that each SNP was associated with HbA1c based on previous association results in whites, despite potential ancestral differences in NHB or MA in linkage disequilibrium (LD) patterns . Since we did not know the effect size of the MAGIC SNPs in non-white populations, we did not apply SNP-specific weights to account for SNP-specific differences in effect on HbA1c, but simply summed the presence of 0, 1, or 2 risk alleles carried by individuals at each SNP. In addition to the 11-SNP GRS, we also performed a secondary analysis using an eight SNP “non-glycemic” risk score by excluding the three glycemic loci (G6PC2, GCK, MTNR1B) for score calculation.
Statistical analyses of association
We stratified the analysis by race-ethnicity (NHB, MA, and NHW) and to estimate rates and proportions within groups used weights to account for sampling probabilities using methods previously described . P-values for differences across race-ethnic groups were calculated using Satterthwaite adjusted- F statistics for continuous variables and chi-square tests for categorical variables. To estimate the significance of differences in allele frequencies across groups we used Fisher’s Exact tests.
To investigate the relationship between SNPs and HbA1c level we used linear regression and an additive genetic model adjusted for age and sex. We included one SNP at a time in the models for individual SNP associations with HbA1c, with genotypes coded as 0, 1 or 2 depending on the number of HbA1c-raising alleles present. To study the collective effect of the 11 SNPs on HbA1c we used linear regression adjusted for age and sex, totaled the number of risk alleles at all 11 SNPs to calculate a risk score, and tested associations of a per-risk-allele increase in genotype risk score with HbA1c. We calculated the adjusted model R 2 with and without the genotype risk score for each group to determine the percent variance in HbA1c explained by genetic effects. The same procedure was carried out for the 8 SNP “non-glycemic” risk score, as well as for genetic associations with mortality (percent dead as of 13.5 years post-baseline exam). To determine if a significant genetic risk score x ethnicity interaction effect on HbA1c exists, we also applied the following linear regression model on the whole sample: Hba1c level (outcome) = sex, age, genetic risk score, ethnicity, genetic risk score x ethnicity interaction. For tests of association with mortality we used logistic regression to estimate the odds of mortality with per-risk-allele increase in HbA1c. For analysis of mortality, Cox models yielded similar results to logistic regression, so Cox model results are not shown. We also applied the following logistic regression model on the whole sample: mortality (outcome) = sex, age, GRS, ethnicity, GRS x ethnicity interaction. For the analyses we used SUDAAN (version 10.0)  and SAS (version 9.2, SAS Institute Inc, Cary, NC). We considered p values less than 0.05 to indicate statistical significance, based on one test per previously established SNP at each locus for each hypothesis (SNP is associated with HbA1c; SNP is associated with mortality).
Linkage disequilibrium, signatures of population differentiation and natural selection at HbA1c-associated loci
To evaluate inter-ethnic differences in LD near the SNPs, we examined 500 kb around each SNP (HapMap Release 27, Build 36, phases II and III) for four populations (CEU, YRI, ASW, and MEX). Using Haploview version 4.2,  we counted the number of “Gabriel” LD regions (based on confidence intervals)  in that region for each population. We investigated natural selection around the ten loci using Haplotter  and HapMap Phase II data. Standardized Integrated Haplotype Score (iHS) (a statistic based on differential LD around positively selected alleles that compares haplotype length with ancestral allele versus derived allele to detect positive selection) , Fay and Wu’s H + statistic (a measure used to scan a region for allele frequencies that are skewed from the neutral model)  and the Fixation Index (FST) (a statistic using allele frequencies to measure genetic divergence between subpopulations)  were obtained through Haplotter SNP queries spanning 2 Mb regions at each locus.
Characteristics of participants
Characteristics of participants by race-ethnicity, Third National Health and Nutrition Examination Survey (NHANES III)
Sample weighted distribution by race-ethnicity1
(n = 1231)
(n = 901)
(n = 909)
HbA 1c (%) (SE)
Male, % (95% CI)
Female, % (95% CI)
BMI (kg/m 2 )
>25 (95% CI)
25 to >30 (95% CI)
> 30 (95% CI)
Risk allele frequencies of HbA1c-associated variants
SNP associations with HbA1c
Regression coefficients of 11 HbA 1c -associated SNPs on HbA 1c levels by race-ethnicity, Third National Health and Nutrition Examination Survey (NHANES III)
p-value for heterogeneity3
Combined associations of 11 HbA1c SNPS with HbA1c
Association of HbA 1c with the 11 SNP genetic risk score by race-ethnicity, Third National Health and Nutrition Examination Survey (NHANES III)
Genetic Risk Score (SE)4
R2 Without Score3
HbA1c (%) difference top - bottom 10% of score distribution
HbA 1c (%)
HbA 1c (%)
HbA 1c (%)
Combined associations of eight non-glycemic SNPs with HbA1c
The mean “non-glycemic” 8-SNP genotype scores (actual scores ranged from 4–15) were 8.80 (± 0.06[SE]) in NHB, 8.72 (± 0.06) in MA and 8.41(± 0.06) in NHW, (p value for global difference across race-ethnicity < 0.0001) ( Additional file 1: Table S4). The per-risk allele increase in the score was significantly associated with HbA1c levels in NHW, but not in NHB and MA.
Association of 11 HbA1c SNPs with mortality
Association of 11 SNPs and the Genotype Score with mortality by race-ethnicity, Third National Health and Nutrition Examination Survey (NHANES III)
Mortality at 13.5 years
with 0, 1, or 2 Risk Allele
SNP per-risk alelle increase in mortality (OR) (95% CI)
Age and race standardized weighted mortality (%) per 1000 person-years (95% CI)
11 SNP Genotype Score per-risk alelle increase in mortality (OR) (95% CI)
Linkage disequilibrium at HbA1c-associated loci
There were consistently fewer LD regions in the CEU population compared to YRI at every locus (YRI:CEU): SPTA1 42:25; ABCB11/G6PC2 49:27; HFE 31:17; GCK 28:21; ANK1 (rs41668351) 35:29; ANK1 (rs41749562) 30:25; HK1 45:38; MTNR1B 39:22; FN3K 42:27; TMPRSS6 78:52; ATP11A/TUBGCP3 49:31 ( Additional file 1: Table 6). ASW, which represents a population with African ancestry in the southwestern United States, only had higher numbers of LD regions compared to CEU in two out of 11 regions, possibly due to lower coverage of ASW compared to CEU (and YRI) in HapMap Release 27.
Evidence of population differentiation and natural selection at HbA1c-associated loci
Fay and Wu’s H + was highly skewed at two loci (HK1 and ATP11A) in CEU ( Additional file 1: Table S7). Integrated haplotype scores (iHS) were not highly negative or positive at these SNPs, as would be characteristic for regions undergoing recent natural selection. FST, a measure of the amount of allelic fixation due to drift, was greater than 15% at ANK1 and ATP11A in both CEU and YRI, suggesting population differentiation at these loci . Haplotter queries by gene did not reveal evidence of natural selection directly at the genes queried, but evidence of natural selection was observed within a 2 Mb region of ABC11/G6PC2 and TMPRSS6 for CEU and YRI, respectively.
Genome-wide association studies of HbA1c levels in cohorts of white individuals of European ancestry revealed a combination of glycemic and non-glycemic biological influences on HbA1c, with three loci associated with HbA1c in or near genes likely involved in glycemic control pathways and seven loci associated with HbA1c in or near genes likely to be involved in erythrocyte biology . In this study we found that in the nationally representative NHANES III sample of US adults, heterogeneity in risk allele frequencies exists across race-ethnic groups for six of these HbA1c-associated SNPs. Five SNP risk allele frequencies in NHB were significantly lower or higher than the other two groups. Risk allele frequencies observed in NHANES III were generally consistent with frequencies of comparable populations available in HapMap, suggesting that HapMap and NHANES III can be considered representative of each other at these SNPs at least with respect to white, African American and Mexican American race-ethnic populations. An 11-HbA1c- associated SNP genotype score was subtly different by race-ethnicity and was associated with increase in HbA1c in NHW and MA but not NHB. The 11-SNP genotype score was not significantly associated with mortality in any group.
There are several potential sources for the inter-race-ethnic heterogeneity of SNP and genotype risk score associations with HbA1c that we observed. One potential source of heterogeneity is race-specific selection acting on erythrocyte-related loci that influence HbA1c. Variants in the β- hemoglobin gene (HBB), for example, produce abnormal erythrocytes that can affect HbA1c levels  but are protective against malaria and are thus maintained in populations and found at highest frequencies in regions historically exposed to this disease like Africa and India . Rare mutations in many loci associated with HbA1c (SPTA1 ANK1 HK1 TMPRSS6) are known to cause hereditary red blood cell disorders  and common variants at several loci (SPTA1, HFE, ANK1 HK1 TMPRSS6) are associated with hematological traits like hemoglobin concentration and mean corpuscular volume [32–34]. Adjustment of models of these common variants predicting HbA1c levels for levels of hemoglobin concentration or mean corpuscular volume attenuate SNP-HbA1c relationships, suggesting mediation of HbA1c varation by elements of erythrocyte biology . Further, a recent genetic association study showed some differences in the genetic regulation of hematological traits in Europeans compared with Africans . Our analyses of differentiation and selection suggest that there may be some selection pressure at the ANK1 HK1 ATP11A, TMPRSS6 and ABC11/G6PC2 loci, the first four of which are erythrocyte-related loci. However, in the present study, race-ethnic differences in association with HbA1c by SNP were observed at only two of these loci (ANK1 [rs4737009] and TMPRSS6). We also examined inter-population allele frequency differences of trait-associated SNPs which may indicate that selection is operating on the trait . While frequencies of some disease-associated alleles have been reported as largely heterogeneous between race-ethnicities [36–39], other data suggest no greater differentiation than would be expected from a random set of SNPs . We found heterogeneous inter-race-ethnic risk allele frequencies at six of the HbA1c-associated SNPs and three of these (SNPs near ANK1 [both SNPs] and TMPRSS6) showed inter-race heterogeneity in SNP association with HbA1c.
We found modest race-ethnic differences in the association of individual or collective HbA1c-associated SNPs and levels of HbA1c. We found nominally significant associations with an HbA1c-associated SNP genotype score and levels of HbA1c in NHW, as expected, and also in MA, but not in NHB individuals. Ancestral variation in LD probably accounts for some of this difference in association. LD is more fine-grained in genomes of African individuals , so some of the HbA1c-associated SNPs may be more tightly linked to putative functional alleles in NHW and MA than in NHB. Modest power given the relatively small sample size of NHANES III could also account for the relatively weak association of HbA1c SNPs with HbA1c in each race-ethnic group ( Additional file 1: Table S3). No significant interactions were observed, also possibly due to low power. T2D diagnosis was based on fasting glucose with no OGTT, which may have introduced misclassification in T2D status of study subjects. Furthermore, greater heterogeneity exists in NHB, and this heterogeneity may have influenced variability in HbA1c levels. Since there are no ancestry markers available in NHANES to evaluate genetic heterogeneity within populations, we were unable to evaluate substructure within ethnic groups and, for the purposes of this study, assumed little to no intra-population substructure.
Despite previous epidemiological associations of HbA1c levels with mortality or cardiovascular disease [12–19] and race-ethnic variation in mortality rates in NHANES III, we did not see any evidence of an association of HbA1c-associated loci with mortality in any race-ethnic group. If HbA1c is associated with mortality, it is likely to be mediated through HbA1c’s association with hyperglycemia and insulin resistance, but many HbA1c-associated loci are associated with erythrocyte biology and not hyperglycemia. A lack of association of the HbA1c-associated SNPs studied here and cardiovascular disease events has also been shown previously in white cohorts . This unlinking of hyperglycemia from HbA1c biology also has bearing on diabetes screening and diagnosis. Another explanation for a lack of association of the HbA1c genetic risk score with mortality is the lack of statistical power due to small sample size within each ethnicity ( Additional file 1: Table S5). When pooling the entire sample and carrying out an interaction model we also observed no significant genetic risk score x ethnicity interaction on mortality.
Race-ethnic differences in HbA1c levels were observed in the present study and have been shown previously [41–46]. Population differences in HbA1c levels are partly attributable to variability in non-biological factors including race-ethnic differences in lifestyle, socioeconomics, health insurance access or screening intensity [41, 44]. Further, there are likely race ethnic differences in non-glycemic biological factors including glycemic level, hemoglobinopathies [30, 47–49], iron deficiency anemias [21, 48, 50–54], and erythrocyte survival [48, 55, 56]. The data suggest that glycemic control is not the only root cause of inter-race-ethnic differences in HbA1c. Although the clinical impact of HbA1c genetics on diabetes detection appears to be modest in whites, at least , whether race-ethnic heterogeneity in HbA1c genetics influences diabetes diagnosis in other race-ethnic groups requires further investigation.
The major strengths of this study include genotyping of all 11 known HbA1c-associated SNPs in the nationally representative, multi-race-ethnic NHANES III cohort. The heterogeneity of HbA1c–associated SNP frequencies across race-ethnic groups and the limited impact of these SNPs on HbA1c level in NHB individuals underscore the importance of extending association studies and the discovery of causal variants to diverse populations for a comprehensive understanding of HbA1c genetic architecture. As diverse populations become increasingly incorporated into genetic studies for variant detection, inter-race-ethnic variation will likely continue to be revealed, necessitating careful investigation of its sources and significance.
In NHANES III there is substantial RAF race-ethnic heterogeneity at many HbA1c loci. An 11-HbA1c- associated SNP genotype score was subtly different by race-ethnicity and was associated with increase in HbA1c in NHW and MA but not NHB. While the numerous potential sources for this race-ethnic heterogeneity in association with HbA1c require further exploration, the data underscore the importance of extending genetic analysis to non-white populations, especially where they may have impact on guidelines for disease screening, diagnosis or management.
The findings and conclusions in this report are those of the author(s) and do not necessarily represent the official position of the Centers for Disease Control and Prevention.
The data are from the NHANES III Public Use and Genetic Data Sets (http://www.cdc.gov/nchs/nhanes/genetics/genetic.htm). Supported by an American Diabetes Association Mentored Post-Doctoral Fellowship Award (Dr. Grimsby), National Institute for Diabetes and Digestive and Kidney Diseases (NIDDK) R01 DK078616 (Dr Meigs), NIDDK K24 DK080140 (Dr Meigs), NIDDK Research Career Award K23 DK65978 (Dr Florez), a Massachusetts General Hospital Physician Scientist Development Award, and a Doris Duke Charitable Foundation Clinical Scientist Development Award (Dr Florez).
The MAGIC Investigators are listed in the on-line supplement. We thank Sekar Kathiresan MD, for assistance in obtaining the NHANES III DNA that we used for genotyping, and Peter Shrader MS for analytic assistance.
The findings and conclusions in this report are those of the author(s) and do not necessarily represent the official position of the Centers for Disease Control and Prevention.
James B. Meigs currently serves on a consultancy board for Interleukin Genetics. Jose C. Florez has received consulting honoraria from Merck, Pfizer, bioStrategies, XOMA and Publicis Healthcare Communications Group, a global advertising agency engaged by Amylin Pharmaceuticals.
- Cowie CC, Rust KF, Ford ES, Eberhardt MS, Byrd-Holt DD, Li CY, Williams DE, Gregg EW, Bainbridge KE, Saydah SH, et al: Full Accounting of Diabetes and Pre-Diabetes in the US Population in 1988–1994 and 2005–2006. Diabetes Care. 2009, 32 (2): 287-294.PubMed CentralView ArticlePubMed
- Karter AJ: Ethnic disparities in diabetic complications in an insured population (vol 287, pg 2519, 2002). JAMA. 2002, 288 (1): 46-View Article
- Narayan KM, Boyle J, Thompson T, Sorensen S, Williamson D: Life years and quality-adjusted life years (QALYs) among people with diabetes. Diabetes. 2003, 52: A10-
- Gary TL, Narayan KMV, Gregg EW, Beckles GLA, Saaddine JB: Racial/ethnic differences in the health care experience of us adults with diabetes. Ethn Dis. 2003, 13 (1): 154-PubMed
- The Diabetes Control and Complications Trial research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Eng J Med. 1993, 329: 977-986.View Article
- UK Prospectuve Diabetes Study (UKPDS): Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998, 352: 837-853.View Article
- Soranzo N, Sanna S, Wheeler E, Gieger C, Radke D, Dupuis J, Bouatia-Naji N, Langenberg C, Prokopenko I, Stolerman E, et al: Common variants at 10 genomic loci influence hemoglobin A(C) levels via glycemic and nonglycemic pathways. Diabetes. 2010, 59 (12): 3229-3239. 10.2337/db10-0502.PubMed CentralView ArticlePubMed
- Hamblin MT, Di Rienzo A: Detection of the signature of natural selection in humans: Evidence from the Duffy blood group locus. Am J Hum Genet. 2000, 66 (5): 1669-1679. 10.1086/302879.PubMed CentralView ArticlePubMed
- Feng ZL, Smith DL, McKenzie FE, Levin SA: Coupling ecology and evolution: malaria and the S-gene across time scales. Math Biosci. 2004, 189 (1): 1-19. 10.1016/j.mbs.2004.01.005.View ArticlePubMed
- Hedrick P: Estimation of relative fitnesses from relative risk data and the predicted future of haemoglobin alleles S and C. J Evol Biol. 2004, 17 (1): 221-224.View ArticlePubMed
- Pare G, Chasman DI, Parker AN, Nathan DM, Miletich JP, Zee RY, Ridker PM: Novel Association of HK1 with Glycated Hemoglobin in a Non-Diabetic Population: A Genome-Wide Evaluation of 14,618 Participants in the Women’s Genome Health Study. Plos Genetics. 2008, 4 (12): e1000312-10.1371/journal.pgen.1000312.PubMed CentralView ArticlePubMed
- Park S, BarrettConnor E, Wingard DL, Shan J, Edelstein S: GHb is a better predictor at cardiovascular disease than fasting or postchallenge plasma glucose in women without diabetes - The Rancho Bernardo Study. Diabetes Care. 1996, 19 (5): 450-456. 10.2337/diacare.19.5.450.View ArticlePubMed
- de Vegt F, Dekker JM, Ruhe HG, Stehouwer CDA, Nijpels G, Bouter LM, Heine RJ: Hyperglycaemia is associated with all-cause and cardiovascular mortality in the Hoorn population: the Hoorn Study. Diabetologia. 1999, 42 (8): 926-931. 10.1007/s001250051249.View ArticlePubMed
- Khaw KT, Wareham N, Luben R, Bingham S, Oakes S, Welch A, Day N: Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of European Prospective Investigation of Cancer and Nutrition (EPIC-Norfolk). Br Med J. 2001, 322 (7277): 15-18B. 10.1136/bmj.322.7277.15.View Article
- Meigs JB, Nathan DM, D'Agostino RB, Wilson PWF: Fasting and postchallenge glycemia and cardiovascular disease risk - The framingham offspring study. Diabetes Care. 2002, 25 (10): 1845-1850. 10.2337/diacare.25.10.1845.View ArticlePubMed
- Blake GJ, Pradhan AD, Manson JE, Williams GR, Buring J, Ridker PM, Glynn RJ: Hemoglobin A(1c) level and future cardiovascular events among women. Arch Intern Med. 2004, 164 (7): 757-761. 10.1001/archinte.164.7.757.View ArticlePubMed
- Khaw KT, Wareham N, Bingham S, Luben R, Welch A, Day N: Association of hemoglobin A(1c) with cardiovascular disease and mortality in adults: The European prospective investigation into cancer in Norfolk. Ann Intern Med. 2004, 141 (6): 413-420.View ArticlePubMed
- Levitan EB, Liu S, Stampfer MJ, Cook NR, Rexrode KM, Ridker PM, Buring JE, Manson JE: HbA(1c) measured in stored erythrocytes and mortality rate among middle-aged and older women. Diabetologia. 2008, 51 (2): 267-275. 10.1007/s00125-007-0882-y.PubMed CentralView ArticlePubMed
- Selvin E, Steffes MW, Zhu H, Matsushita K, Wagenknecht L, Pankow J, Coresh J, Brancati FL: Glycated Hemoglobin, Diabetes, and Cardiovascular Risk in Nondiabetic Adults. N Eng J Med. 2010, 362 (9): 800-811. 10.1056/NEJMoa0908359.View Article
- Prevention CfDCa: Plan and operation of the Third National Health and Nutrition Examination Survey, 1988–94. Series 1: programs and collection procedures. Vital Health Stat. 1994, 32: 1-407.
- Kim C, Bullard KM, Herman WH, Beckles GL: Association between iron deficiency and A1C Levels among adults without diabetes in the National Health and Nutrition Examination Survey, 1999–2006. Diabetes Care. 2010, 33 (4): 780-785. 10.2337/dc09-0836.PubMed CentralView ArticlePubMed
- Reich DE, Cargill M, Bolk S, Ireland J, Sabeti PC, Richter DJ, Lavery T, Kouyoumjian R, Farhadian SF, Ward R, et al: Linkage disequilibrium in the human genome. Nature. 2001, 411 (6834): 199-204. 10.1038/35075590.View ArticlePubMed
- Lohr S: Sampling: design and analysis. 1999, Pacific Grove, CA
- Shah VB, Bieler G: SUDAAN User's Manual, Release 9.0. 2005, Research Triangle Park, NC
- Barrett JC, Fry B, Maller J, Daly MJ: Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics. 2005, 21 (2): 263-265. 10.1093/bioinformatics/bth457.View ArticlePubMed
- Gabriel SB, Schaffner SF, Nguyen H, Moore JM, Roy J, Blumenstiel B, Higgins J, DeFelice M, Lochner A, Faggart M, et al: The structure of haplotype blocks in the human genome. Science. 2002, 296 (5576): 2225-2229. 10.1126/science.1069424.View ArticlePubMed
- Voight BF, Kudaravalli S, Wen X, Pritchard JK: A map of recent positive selection in the human genome. PLoS Biol. 2006, 4 (3): e72-10.1371/journal.pbio.0040072.PubMed CentralView ArticlePubMed
- Fay JC, Wu CI: Hitchhiking under positive Darwinian selection. Genetics. 2000, 155 (3): 1405-1413.PubMed CentralPubMed
- Wright S: Evolution and the Genetics of Populations. Variability within and among Natural Populations, vol. 4. 1978, University of Chicago Press
- Roberts WL, Safar-Pour S, De BK, Rohlfing CL, Weykamp CW, Little RR: Effects of hemoglobin C and S traits on glycohemoglobin measurements by eleven methods. Clin Chem. 2005, 51 (4): 776-778. 10.1373/clinchem.2004.047142.View ArticlePubMed
- Kwiatkowski DP: How malaria has affected the human genome and what human genetics can teach us about malaria. Am J Hum Genet. 2005, 77 (2): 171-192. 10.1086/432519.PubMed CentralView ArticlePubMed
- Soranzo N, Spector TD, Mangino M, Kuhnel B, Rendon A, Teumer A, Willenborg C, Wright B, Chen L, Li M, et al: A genome-wide meta-analysis identifies 22 loci associated with eight hematological parameters in the HaemGen consortium. Nat Genet. 2009, 41 (11): 1182-1190. 10.1038/ng.467.PubMed CentralView ArticlePubMed
- Ganesh SK, Zakai NA, van Rooij FJ, Soranzo N, Smith AV, Nalls MA, Chen MH, Kottgen A, Glazer NL, Dehghan A, et al: Multiple loci influence erythrocyte phenotypes in the CHARGE Consortium. Nat Genet. 2009, 41 (11): 1191-1198. 10.1038/ng.466.PubMed CentralView ArticlePubMed
- Andrews NC: Genes determining blood cell traits. Nat Genet. 2009, 41 (11): 1161-1162. 10.1038/ng1109-1161.View ArticlePubMed
- Lo KS, Wilson JG, Lange LA, Folsom AR, Galarneau G, Ganesh SK, Grant SF, Keating BJ, McCarroll SA, Mohler ER, et al: Genetic association analysis highlights new loci that modulate hematological trait variation in Caucasians and African Americans. Hum Genet. 2011, 129 (3): 307-317. 10.1007/s00439-010-0925-1.PubMed CentralView ArticlePubMed
- Myles S, Davison D, Barrett J, Stoneking M, Timpson N: Worldwide population differentiation at disease-associated SNPs. BMC Med Genomics. 2008, 1: 22-10.1186/1755-8794-1-22.PubMed CentralView ArticlePubMed
- Ioannidis JPA, Ntzani EE, Trikalinos TA: 'Racial' differences in genetic effects for complex diseases. Nat Genet. 2004, 36 (12): 1312-1318. 10.1038/ng1474.View ArticlePubMed
- Mattei J, Parnell LD, Lai CQ, Garcia-Bailo B, Adiconis X, Shen J, Arnett D, Demissie S, Tucker KL, Ordovas JM: Disparities in allele frequencies and population differentiation for 101 disease-associated single nucleotide polymorphisms between Puerto Ricans and non-Hispanic whites. BMC Genet. 2009, 10: 12-View Article
- Adeyemo A, Rotimi C: Genetic Variants Associated with Complex Human Diseases Show Wide Variation across Multiple Populations. Public Health Genomics. 2010, 13 (2): 72-79. 10.1159/000218711.View ArticlePubMed
- Lohmueller KE, Mauney MM, Reich D, Braverman JM: Variants associated with common disease are not unusually differentiated in frequency across populations. Am J Hum Genet. 2006, 78 (1): 130-136. 10.1086/499287.PubMed CentralView ArticlePubMed
- Kirk JK, D'Agostino RB, Bell RA, Passmore LV, Bonds DE, Karter AJ, Narayan KMV: Disparities in HbA(1c) levels between African-American and non-Hispanic white adults with diabetes - A meta-analysis. Diabetes Care. 2006, 29 (9): 2130-2136. 10.2337/dc05-1973.PubMed CentralView ArticlePubMed
- Herman WH, Ma Y, Uwaifo G, Haffner S, Kahn SE, Horton ES, Lachin JM, Montez MG, Brenneman T, Barrett-Connor E, et al: Differences in A1C by race and ethnicity among patients with impaired glucose tolerance in the diabetes prevention program. Diabetes Care. 2007, 30 (10): 2453-2457. 10.2337/dc06-2003.PubMed CentralView ArticlePubMed
- Adams AS, Trinacty CM, Zhang F, Kleinman K, Grant RW, Meigs JB, Soumerai SB, Ross-Degnan D: Medication adherence and racial differences in A1C control. Diabetes Care. 2008, 31 (5): 916-921. 10.2337/dc07-1924.PubMed CentralView ArticlePubMed
- Kirk JK, Passmore LV, Bell RA, Narayan KMV, D'Agostino RB, Arcury TA, Quandt SA: Disparities in A1C Levels Between Hispanic and Non-Hispanic White Adults With Diabetes A meta-analysis. Diabetes Care. 2008, 31 (2): 240-246.View ArticlePubMed
- Herman WH, Dungan KM, Wolffenbuttel BHR, Buse JB, Fahrbach JL, Jiang HH, Martin S: Racial and Ethnic Differences in Mean Plasma Glucose, Hemoglobin A(1c), and 1,5-Anhydroglucitol in Over 2000 Patients with Type 2 Diabetes. J Clin Endocrinol Metab. 2009, 94 (5): 1689-1694. 10.1210/jc.2008-1940.View ArticlePubMed
- Selvin E, Zhu H, Brancati FL: Elevated A1C in Adults Without a History of Diabetes in the US. Diabetes Care. 2009, 32 (5): 828-833. 10.2337/dc08-1699.PubMed CentralView ArticlePubMed
- Bisse E, Schauber C, Zorn N, Epting T, Eigel A, Van Dorsselaer A, Wieland H, Kister J, Kiger L: Hemoglobin Gorwihl alpha(2)beta(2)5(A2)Pro - > Ala, an electrophoretically silent variant with impaired glycation. Clin Chem. 2003, 49 (1): 137-143. 10.1373/49.1.137.View ArticlePubMed
- Kilpatrick E: Haemoglobin A1c in the diagnosis and monitoring of diabetes mellitus. J Clin Pathol. 2007, 61: 977-982.View Article
- Lee ST, Weykamp CW, Lee YW, Kim JW, Ki CS: Effects of 7 hemoglobin variants on the measurement of glycohemoglobin by 14 analytical methods. Clin Chem. 2007, 53 (12): 2202-2205. 10.1373/clinchem.2007.093963.View ArticlePubMed
- Brooks AP, Metcalfe J, Day JL, Edwards MS: Iron-deficiency and glycosylated hemoglobin-a1. Lancet. 1980, 2 (8186): 141-View ArticlePubMed
- Davis RE, McCann VJ, Nicol DJ: Influence of iron-deficiency anemia on the glycosylated hemoglobin level in a patient with diabetes-mellitus. Med J Aust. 1983, 1 (1): 40-41.PubMed
- Tarim O, Kucukerdogan A, Gunay U, Eralp O, Ercan I: Effects of iron deficiency anemia on hemoglobin A(1c) in type 1 diabetes mellitus. Pediatr Int. 1999, 41 (4): 357-362.View ArticlePubMed
- El-Agouza I, Abu Shahla A, Sirdah M: The effect of iron deficiency anaemia on the levels of haemoglobin subtypes: possible consequences for clinical diagnosis. Clin Lab Haematol. 2002, 24 (5): 285-289. 10.1046/j.1365-2257.2002.00464.x.View ArticlePubMed
- Coban E, Ozdogan M, Timuragaoglu A: Effect of iron deficiency anemia on the levels of hemoglobin A1c in nondiabetic patients. Acta Haematol. 2004, 112 (3): 126-128. 10.1159/000079722.View ArticlePubMed
- Panzer S, Kronik G, Lechner K, Bettelheim P, Neumann E, Dudczak R: Glycosylated hemoglobins (ghb) - an index of red-cell survival. Blood. 1982, 59 (6): 1348-1350.PubMed
- Cohen RM, Franco RS, Khera PK, Smith EP, Lindsell CJ, Ciraolo PJ, Palascak MB, Joiner CH: Red cell life span heterogeneity in hematologically normal people is sufficient to alter HbA1c. Blood. 2008, 112 (10): 4284-4291. 10.1182/blood-2008-04-154112.PubMed CentralView ArticlePubMed
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2350/13/30/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.